Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $35.95 USD
Change Today -0.17 / -0.47%
Volume 578.3K
HAE On Other Exchanges
New York
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Christopher J. Lindop

Chief Financial Officer and Executive Vice President of Business Development,Haemonetics Corporation
AgeTotal Calculated CompensationThis person is connected to 11 board members in 2 different organizations across 4 different industries.

See Board Relationships
As of Fiscal Year 2015


Mr. Christopher J. Lindop, also known as Chris has been the Chief Financial Officer of Haemonetics Corporation since January 2007 and serves as its Executive Vice President of Business Development. Mr. Lindop served as Vice President of Finance at Haemonetics Corp. since January 2007. He served as Chief Financial Officer of Alere Inc. (formerly, Inverness Medical Innovations Inc.) from September 22, 2003 to December 11, 2006 and also served as its Principal Accounting ...

Read Full Background

Corporate Headquarters*

400 Wood Road
Braintree, Massachusetts 02184

United States

Phone: 781-848-7100
Fax: --

Board Members Memberships*

Director, Chairman of Audit & Finance Committee and Member of Nominating & Corporate Governance Committee


Unknown/Other Education
University of Strathclyde

Other Affiliations*

Annual Compensation*

Total Annual Compensation$478,260

Stock Options*

Restricted Stock Awards$562,464
All Other Compensation$6,900
Exercised Options Value$87,987
Exercisable Options189,994
Exercisable Options Value$2,699,214
Unexercisable Options94,507
Unexercisable Options Value$599,636
Total Value of Options$3,386,836
Total Number of Options284,501

Total Compensation*

Total Annual Cash Compensation$696,968
Total Short Term Compensation$478,260
Other Long Term Compensation$569,364
Total Calculated Compensation$1,446,929
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HAE:US $35.95 USD -0.17


Omar S. Ishrak Chairman and Chief Executive Officer
Medtronic plc
Yutaro Shintaku President and Representative Director
Terumo Corporation
Ulf M. Schneider Chairman of the Management Board - Fresenius Management Se, Chief Executive Officer of Fresenius Management Se and President of Fresenius Management Se
Fresenius SE & Co KGaA
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAEMONETICS CORP/MASS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at